Privium Fund Management UK Ltd Makes New $1.59 Million Investment in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Privium Fund Management UK Ltd purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,600 shares of the exchange traded fund’s stock, valued at approximately $1,588,000. SPDR S&P Biotech ETF makes up about 1.1% of Privium Fund Management UK Ltd’s holdings, making the stock its 29th biggest position.

A number of other large investors also recently modified their holdings of XBI. EPG Wealth Management LLC grew its position in SPDR S&P Biotech ETF by 152.7% during the third quarter. EPG Wealth Management LLC now owns 460 shares of the exchange traded fund’s stock worth $34,000 after buying an additional 278 shares in the last quarter. BOCHK Asset Management Ltd purchased a new position in shares of SPDR S&P Biotech ETF during the fourth quarter worth about $36,000. Tennessee Valley Asset Management Partners bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth approximately $44,000. Wetzel Investment Advisors Inc. purchased a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $45,000. Finally, Concourse Financial Group Securities Inc. raised its stake in SPDR S&P Biotech ETF by 21.2% in the fourth quarter. Concourse Financial Group Securities Inc. now owns 658 shares of the exchange traded fund’s stock valued at $59,000 after purchasing an additional 115 shares in the last quarter.

SPDR S&P Biotech ETF Price Performance

XBI stock traded down $1.43 during midday trading on Friday, reaching $91.39. The company had a trading volume of 8,582,705 shares, compared to its average volume of 11,094,247. The firm has a 50-day moving average price of $89.00 and a 200-day moving average price of $88.94. The company has a market capitalization of $6.97 billion, a P/E ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 1 year low of $63.80 and a 1 year high of $103.52.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.